SIDI together with Karilinska Institut organizes the workshop that is about user adapted knowledge bases and real world data in medicine and pharmacology: data acquisition, design, implementation and effects with the detailed aims of:
1. Provide state-of-the-art knowledge about design and use of knowledge bases and real world data to achieve rational drug therapy in clinical practice.
2. Strengthen research and development about decision support for patients, healthcare staff and students.
3. Highlight optimal avenues to access data and sustain open science collaboration.
4. Identify and initiate research and development partnerships.
More information in the attached files: invitation, Programme, Practical

SIDI co-organises meeting about medical information

The Swedish Society of Medicine and SIDI organise a hearing about the availability of medical information on the 30th of May.
Programme and information about participation can be found in the attached PDF file (in Swedish).

BIKT agreement

SIDI and Inera have agreed on cooperation to produce the database BIKT (from the Swedish "Biverkningsöversikt" = Summary of adverse effects).
BIKT is a dataset containing information about undesirable adverse effects of medicinal drugs in  the Swedish market. BIKT covers at this moment about 50% of all medicinal drugs in the Swedish market and the ambition in the agreement is to constantly increase this figure all the time.
SIDI is going to deliver an updated and quality assured database once  a month to be integrated in the Sil database from Inera. The Sil database is used for decision support in the drug's prescription modules in the majority of the EHR systems in Sweden.

SIDI at Vitalis

Our CTO and board member Daniel Rodriguez is going to have a talk in the Vitalis conference th 24th April at 13.30 hs with the title:
    Future medical decision support requires open data and software and user-driven development.
The Vitalis conference is the largest eHealth event in Scandinavia.It takes place 22-24 April 2015 in Gothenburg.

Drugline, online for more than a year.

The database Drugline has now been openly availiable for more than a year. Information about the project and the final report can be found here:

Drugline launched

SIDI, together with the drug information central at Karolinska University Hospital is launching the database Drugline on the 1st of January. The database contains approximately 14 000 questions and answers form drug information centers in Sweden, Odense in Denmark and Turku in Finland. Most of the documents are about adverse effects of drugs, drug interactions and drug use during pregnancy and lactation but many other drug related questions have also been answered.  The database can be found on the URL and is open for anyone although the documents are written and intended for health care personnel.  The project is supported by the Internet fund (
SIDI has contributed with the technical infrastructure of the search engine Drugle which is in the bottom of the Drugline solution. The project has been driven by Karolinska University Hospital together with Seibo Software Studios (Sweden) and Sophhilabs (Uruguay).


Open access to Drugline, - a project at department of clinical pharmacology Karolinska University Hospital in collaboration with SIDI supported by Internetfonden.

The department of Clinical Pharmacology at Karolinska University Hospital has received a grant by Internetfonden for making the database Drugline openly available. The project started in June 2012 and the aim is to launch the open version of Drugline on the 1st January 2013. The project will be done in collaboration with SIDI and the database will be accessible from the SIDI site.
Drugline is a full-text database with evaluated drug information. The database was developed in 1984 at the Drug Information Centre (Karolic), Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. It contains questions and answers, which have been handled by the regional Drug Information Centres in Sweden, Odense (Denmark), and Turku (Finland). Karolic is responsible for the administration of Drugline. The questions in the database are patient related and concern adverse effects, drug interactions, drug therapy and drug treatment during pregnancy and lactation.
Drugline contains over 14 000 documents. The documents within the database are written in Swedish or English. Drugline containes approximately 35% questions and answers in English and the proportion of English documents is steadily increasing.
Searching in the new database will be done using the search engine Drugle. Drugle is a semantic search engine for pharmacology and medical drug information.
Today the database is available by subscription and the usage is therefore limited. The aim of the project is to make it openly available and thereby increase the use mainly by health care personnel.
Project description (in Swedish), press release (in Swedish).

New Project: Swedish reference model for drug information

SIDI is launching a new project based on the preliminary work from Seibo Software Studios:

Swedish reference model for drug information

The purpose of this project is the creation of a conceptual model of drug information to be used as a reference primarily in Sweden in EDS systems on drugs in health care.

More info: Projects page 

Unique evaluation of two drug-drug interaction databases for expert support in healthcare and in pharmacy

by Prof. Dr. Lars L. Gustafsson

A few days ago Swedish Medical Products Agency (MPA) published a unique comparison of two drug-drug interaction databases called EES (Drug-Drug interactions in the Electronic Expert Support provided by The Information Service Board for Swedish Pharmacies) and SFINX

The Drug-Drug Interaction Function in EES is originally developed by the US Company First Databank and intended to be used as an Electronic Decision Support for pharmacists when dispensing drugs at pharmacies. SFINX is developed primarily for use as a decision support system for physicians and nurses in drug prescribing by clinical pharmacologists and pharmacists at Karolinska Institutet in Stockholm, at the Finnish Company Medbase and by experts at Stockholm Healthcare Region (1-3).

The responsible officer for the evaluation is Anders Carlsten in collaboration with internal and external experts at Swedish Medical Products Agency. The Swedish Ministry of Health has ordered this comparative study ( ). This is initiated by discussions in Sweden about risks to have two different knowledge databases for drug-drug interactions but also a firm commitment by the Minister of Health to provide a number of EES functions not only at pharmacies but also at Swedish healthcare institutions ( It is quite amazing that this comparison between EES interaction function and SFINX was initiated by a Ministry led by a politician, Göran Hägglund, and not by the National Board of Health and Welfare ( in charge of providing Swedish Healthcare Institutions with guidelines on best practices.

The evaluation is in Swedish but of great interest for everyone interested in how healthcare staff should be supported with scientifically based advice at point of care in future. The evaluation recommends SFINX to be used preferably as decision support in pharmacies and in healthcare institutions . The advantage is that SFINX has drug-drug interaction alerts based on each substance in comparison with the EES drug-drug interaction function that mostly has shared drug-drug interaction alerts for a class of drugs. In addition, EES drug-drug interaction function lacks information for about 22% of available drug substances in Sweden. Dr Anders Carlsten also comment that it is not optimal if two different knowledge databases with different classification systems (3 for EES drug-drug interaction function and 4 for SFINX) are used simultaneously in the country.

A thrilling time is in front of us. The intention from the Minister has been to provide the whole contents of EES, including the drug-drug interaction function, to all Swedish physicians ( but this evaluation recommends SFINX to be used at all pharmacies in Sweden. How will the decision be taken on what drug-drug interaction database should be used be used electronically at point of care and at pharmacies when dispensing drugs in Sweden? Is the minister to take the decision or is it the National Board of Health and Welfare making the decision based on recommendations from their scientific experts? I do hope that the evaluation of MPA is published in English. This evaluation shows that the question on what knowledge databases should be used in healthcare is hot. In my mind, it is self-evident that we only need knowledge databases that are based on scientific findings and developed in an open matter and freely available in the public domain. The risks to use different drug-drug interaction information in pharmacies and in healthcare institutions in the same country is not known but is likely not negligible.


1. Tillgängliggörande av EES för vårdgivare. Rapport: Utvärdering och införande av ESS. 2011-03-17. Apotekens Service AB.

2. Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B. SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009;65:627-33 (

3. Eiermann B, Bastholm-Rahmner P, Korkmaz S, Lilja B, Veg A, Wettermark B, Gustafsson LL. Knowledge databases for clinical decision support in drug prescribing- development, quality assurance, management, integration, implementation and evaluation of clinical value. Decision Support Systems, Book edited by: Chiang S. Jao, ISBN 978-953-7619-64-00, January 2010, INTECH,

Syndicate content